Stacey Vallejo, MD
Pulmonary Disease · Nashville, TNNPI 1831289255
Payments from drug & device makers
Across 338 payments — averaging $26.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Actelion Pharmaceuticals US, Inc.$2K
- GSK$1K
- Boehringer Ingelheim$522
- Insmed, Inc.$405
- AstraZeneca$360
- plus $2K from 23 others
What the payments were for
- Travel & lodging$1231%
- Food & beverage$5,88065%
- Education$3,07534%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 3 | $3,152 |
| Actelion Pharmaceuticals US, Inc. | 103 | $1,887 |
| GSK | 89 | $1,158 |
| Boehringer Ingelheim | 23 | $522 |
| Insmed, Inc. | 15 | $405 |
| AstraZeneca | 26 | $360 |
| Sanofi | 9 | $206 |
| Mylan Specialty L.p. | 10 | $175 |
| Regeneron Healthcare Solutions, Inc. | 7 | $146 |
| Merck | 5 | $132 |
| United Therapeutics Corporation | 6 | $126 |
| Pfizer | 7 | $120 |
| Electromed, Inc. | 7 | $119 |
| Grifols USA, LLC | 2 | $65 |
| Viatris Specialty LLC | 3 | $61 |
| Mallinckrodt Enterprises LLC | 2 | $52 |
| Inspire Medical Systems, Inc. | 2 | $52 |
| Sunovion Pharmaceuticals Inc. | 4 | $52 |
| Inari Medical, Inc. | 1 | $45 |
| Genentech USA, Inc. | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Novartis | 2 | $29 |
| Boston Scientific | 2 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| 3b Medical, Inc. | 1 | $21 |
| ANI Pharmaceuticals, Inc. | 1 | $20 |
| Philips North America LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,123
How this compares
$9,078 in reported general payments places this provider in the 65th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 456 | $365,713 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $221,769 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 124 | $96,751 |
| Breo ElliptaFluticasone/Vilanterol | 152 | $69,802 |
| Spiriva RespimatTiotropium Bromide | 99 | $57,170 |
| EsbrietPirfenidone | 11 | $49,831 |
| Spiriva HandihalerTiotropium Bromide | 51 | $28,981 |
| EliquisApixaban | 27 | $25,008 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $18,590 |
| Incruse ElliptaUmeclidinium Bromide | 51 | $16,783 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $16,269 |
| Atrovent HfaIpratropium Bromide | 20 | $12,751 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $11,197 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 357 | $10,193 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 51 | $8,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,158 | $474,956709 claims |
| Grifols USA, LLCProlastin C | $65 | $221,76913 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $360 | $107,948160 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $522 | $81,829142 claims |
| Genentech USA, Inc.Esbriet | $43 | $49,83111 claims |
| PfizerEliquis | $120 | $25,00827 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $18 | $2,62211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Nashville
- Fabien MaldonadoNashville$2.5M
- James TolleNashville$2.3M
- Lisa LancasterNashville$1.6M
- Ivan RobbinsNashville$1.3M
- Otis RickmanNashville$426K
- Jonathan KropskiNashville$419K
- Justin HewlettNashville$388K
- Susan GarwoodNashville$351K
- Margaret SalisburyNashville$345K
- Joao DeandradeNashville$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.